The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to prevent drug companies from implementing a 340B rebate model. The brief was filed in a consolidated appeal involving five drug companies. The AHA said such models from drug companies would devastate hospitals financially.  

 

“In a world of finite resources, 340B hospitals will have no choice but to divert funds away from patient services and towards burdensome compliance,” the AHA wrote. “All of these consequences ‘frustrate’ the goal of the 340B statute.” 

Authored in-house by Chad Golder, AHA general counsel, the AHA was joined in the filing by the Children’s Hospital Association, the Association of American Medical Colleges and America’s Essential Hospitals.

Related News Articles

Headline
The federal government shutdown will continue as the Senate Oct. 3 failed to adopt a government funding deal. The latest attempt to pass the House-passed…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The federal government shut down Oct. 1 following a failed Senate vote on the House-passed continuing resolution to fund the government by midnight Sept. 30.…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
States have until Sept. 30 to submit an optional letter of intent to the Centers for Medicare & Medicaid Services indicating they plan to apply to the…
Headline
Ashley Thompson, AHA senior vice president of public policy analysis and development, participated in a panel discussion during Modern Healthcare's Leadership…